CRISPR Therapeutics AG
CRSP
$48.41
-$2.04-4.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -89.11% | -90.59% | -81.10% | -81.18% | -86.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -89.11% | -90.59% | -81.10% | -81.18% | -86.13% |
| Cost of Revenue | 10.29% | 15.64% | -4.46% | -13.24% | -12.20% |
| Gross Profit | -19.65% | -25.71% | -55.09% | -35.40% | -76.34% |
| SG&A Expenses | -3.89% | 0.77% | 2.71% | 2.15% | 3.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.23% | 13.49% | -3.50% | -11.25% | -10.22% |
| Operating Income | -15.97% | -21.81% | -43.85% | -28.63% | -58.86% |
| Income Before Tax | -48.07% | -59.37% | -104.92% | -76.26% | -77.66% |
| Income Tax Expenses | -15.31% | 1.31% | 19.23% | 49.74% | 73.30% |
| Earnings from Continuing Operations | -47.42% | -58.80% | -103.80% | -75.99% | -77.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.42% | -58.80% | -103.80% | -75.99% | -77.61% |
| EBIT | -15.97% | -21.81% | -43.85% | -28.63% | -58.86% |
| EBITDA | -16.66% | -22.70% | -46.76% | -30.45% | -63.16% |
| EPS Basic | -37.55% | -49.46% | -99.22% | -69.20% | -67.30% |
| Normalized Basic EPS | -13.42% | -24.37% | -60.35% | -34.61% | -67.36% |
| EPS Diluted | -37.66% | -49.40% | -97.13% | -67.70% | -65.52% |
| Normalized Diluted EPS | -13.42% | -24.37% | -59.04% | -33.65% | -65.95% |
| Average Basic Shares Outstanding | 8.24% | 6.57% | 5.47% | 5.49% | 6.74% |
| Average Diluted Shares Outstanding | 8.24% | 6.57% | 4.95% | 4.96% | 6.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |